Diversity-oriented synthesis, or DOS, enables the rapid and
systematic synthesis of multiple related compounds from small sets of molecules
and reactants. By creatively choosing the chemistry, DOS practitioners can selectively
generate all diastereomers and produce more complicated molecules than are
usually found in commercial screening collections. While much of the attention
has been focused on larger molecules, DOS offers clear applications for addressing
the chemistry challenges of FBLD. This is illustrated nicely by a recent paper
in ACS Med. Chem. Lett. by Alvin
Hung, Damian Young, and collaborators at the Broad Institute, Harvard, the
Albert Einstein College of Medicine, A-STAR, and Baylor College of Medicine.
The researchers started with a very small (86 fragment)
library, which Damian is in the process of expanding to 3000 compounds.
Differential scanning fluorimetry was used to screen the molecules against the
kinase GSK3β, which is implicated in cancer and Alzheimer’s disease. Three
related fragments slightly increased the melting temperature of the enzyme, of
which the simplest was compound 1S.
One nice feature of DOS is that – by design – analog
synthesis is straightforward. Thus the researchers made a dozen or so
derivatives to flesh out the SAR. This revealed that the enantiomer, compound
1R, stabilized the protein even more than the initial hit. STD and WaterLOGSY
NMR confirmed binding, and isothermal titration calorimetry (ITC) revealed modest
but measurable affinity. Synthesis of a few additional analogs led to compound
15R, with low micromolar affinity as assessed both by ITC and an enzymatic
assay. Ligand efficiency was also good, though the ligand efficiency by atom
number (LEAN) values of the molecules do not quite meet Teddy’s Safran Zunft Challenge – a wager due to be settled at FBLD 2016 in a few weeks.
A key selling point of DOS is that, by accelerating
chemistry, it enables optimization even without structural information. In this
case the researchers suspected that the fragment binds in the hinge region of
the kinase, and subsequent crystallography revealed that this was indeed so.
Interestingly though, the quality of the crystal structure was insufficient to
unambiguously place compound 1R; perhaps it binds in multiple conformations. The
crystal structure of compound 15R, on the other hand, was clear.
Of course, there is still a long way to go for this series, and it
remains to be seen how broadly applicable DOS will be for FBLD. I look forward
to seeing additional examples.
No comments:
Post a Comment